This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Archived

This page has been archived on the Web.

Health product recall

Rasilez

Starting date:
May 6, 2013
Posting date:
May 28, 2013
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type III
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-33691

Recalled Products

  1. Rasilez

Reason

Small number of cartons (estimated 330 cartons) with Spanish language and incorrect UPC numbers were in the shipment of Canadian product. However, the product, leaflet and blister card inside are the correct materials for the Canadian market.

Depth of distribution

Wholesalers

Affected products

A. Rasilez

DIN, NPN, DIN-HIM
DIN 02302071
Dosage form
  • Tablet
Strength
  • 300 mg
Lot or serial number
  • T1456A
Companies
Recalling Firm
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval
H9S 1A9
Quebec
CANADA
Marketing Authorization Holder
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.
Dorval
H9S 1A9
Quebec
CANADA

Date modified: